Drug Profile
Research programme: retinitis pigmentosa therapeutics - Takeda
Alternative Names: BIK-406; SHP-630Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BIKAM Pharmaceuticals
- Developer Foundation Fighting Blindness; Takeda
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 23 Oct 2015 Preclinical trials in Retinitis pigmentosa in USA (unspecified route)